Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 159.49M | 75.62M | 14.98M | 5.76M | 1.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 159.49M | 75.62M | 14.98M | 5.76M | 1.06M |
| Cost of Revenue | 62.28M | 62.28M | 50.99M | 51.80M | 51.80M |
| Gross Profit | 97.21M | 13.34M | -36.01M | -46.04M | -50.73M |
| SG&A Expenses | 41.17M | 41.48M | 40.00M | 40.41M | 39.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.62M | 156.73M | 143.95M | 145.18M | 145.06M |
| Operating Income | -2.13M | -81.11M | -128.98M | -139.42M | -144.00M |
| Income Before Tax | 9.46M | -70.13M | -119.01M | -129.93M | -134.86M |
| Income Tax Expenses | 3.31M | 2.57M | 384.00K | 483.00K | 421.00K |
| Earnings from Continuing Operations | 6.15 | -72.70 | -119.39 | -130.41 | -135.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.15M | -72.70M | -119.39M | -130.41M | -135.28M |
| EBIT | -2.13M | -81.11M | -128.98M | -139.42M | -144.00M |
| EBITDA | 6.14M | -72.99M | -121.07M | -131.78M | -137.03M |
| EPS Basic | 0.02 | -1.08 | -1.83 | -2.24 | -2.53 |
| Normalized Basic EPS | 0.04 | -0.66 | -1.14 | -1.40 | -1.57 |
| EPS Diluted | 0.02 | -1.08 | -1.83 | -2.24 | -2.53 |
| Normalized Diluted EPS | 0.03 | -0.66 | -1.14 | -1.40 | -1.57 |
| Average Basic Shares Outstanding | 317.51M | 295.52M | 270.33M | 238.13M | 216.33M |
| Average Diluted Shares Outstanding | 318.32M | 295.52M | 270.33M | 238.13M | 216.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |